ACADIA Pharmaceuticals (ACAD) Receiving Somewhat Positive News Coverage, Study Finds

News stories about ACADIA Pharmaceuticals (NASDAQ:ACAD) have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ACADIA Pharmaceuticals earned a coverage optimism score of 0.02 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.6083635072548 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of ACADIA Pharmaceuticals traded up $1.01, reaching $14.92, during trading hours on Friday, MarketBeat reports. 4,294,264 shares of the stock traded hands, compared to its average volume of 2,911,928. The company has a market cap of $1.74 billion, a P/E ratio of -6.32 and a beta of 3.58. ACADIA Pharmaceuticals has a one year low of $12.77 and a one year high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.06). The firm had revenue of $57.06 million for the quarter, compared to the consensus estimate of $58.63 million. ACADIA Pharmaceuticals had a negative net margin of 135.99% and a negative return on equity of 78.56%. The company’s revenue for the quarter was up 87.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.55) earnings per share. equities research analysts forecast that ACADIA Pharmaceuticals will post -1.95 EPS for the current fiscal year.

Several equities research analysts recently commented on the company. JMP Securities reduced their price objective on ACADIA Pharmaceuticals from $50.00 to $27.00 and set a “market outperform” rating for the company in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday. BidaskClub downgraded ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Stifel Nicolaus assumed coverage on ACADIA Pharmaceuticals in a report on Tuesday, August 7th. They issued a “hold” rating and a $17.00 price objective for the company. Finally, Piper Jaffray Companies downgraded ACADIA Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $19.00 price objective for the company. in a report on Monday, August 6th. Three analysts have rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $39.50.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Further Reading: How to Invest in Growth Stocks

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply